ORB-011
/ Orionis
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
August 26, 2025
ORB-011 In Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=55 | Active, not recruiting | Sponsor: Orionis Biosciences Inc | Trial primary completion date: Jun 2025 ➔ Dec 2025
Trial primary completion date • Breast Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
April 25, 2025
ORB-011 In Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=55 | Active, not recruiting | Sponsor: Orionis Biosciences Inc | Recruiting ➔ Active, not recruiting | N=36 ➔ 55
Enrollment change • Enrollment closed • Breast Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
March 25, 2025
ORB-011 in Patients with Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Orionis Biosciences Inc | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Aug 2025
Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
November 15, 2023
Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors
(Businesswire)
- "Orionis Biosciences...announced that the first patient has been dosed in a Phase 1 clinical trial of ORB-011, an attenuated, cis-targeted interferon immunotherapy based on the company’s A-Kine platform....ORB-011 is a first-in-class modified interferon designed to act with a high level of precision on cDC1 dendritic immune cells, potent activators of tumor cell killing CD8+ T cells."
Trial status • Solid Tumor
August 14, 2023
ORB-011 In Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Orionis Biosciences Inc | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
July 17, 2023
ORB-011 In Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Orionis Biosciences Inc
New P1 trial • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
1 to 6
Of
6
Go to page
1